Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG plc: Publication of positive data from TRX4 type 1 diabetes study

BTG : 27 September, 2006  (Company News)
BTG plc, the medical innovations company, notes that TolerRx, Inc., BTG
BTG plc, the medical innovations company, notes that TolerRx, Inc., BTG’s licensee for the anti-CD3 technology, has announced publication of positive Phase II data on TRX4 (ChAglyCD3), showing that a six-day course of TRX4 therapy in patients with type 1 diabetes reduced the amount of insulin needed to control blood glucose levels for at least 18 months.

Louise Makin, Chief Executive Officer of BTG, commented:
“This study suggests TRX4 could be a real step forward in the treatment of type 1 diabetes. We look forward to further progress by TolerRx in developing this novel therapy.”

TRX4 is one of six pharmaceuticals commercialised by BTG that are currently under clinical development by BTG’s licensees. BTG has three other products undergoing clinical studies prior to commercialisation.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo